Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Applied Therapeutics Inc (APLT)
NASDAQ:APLT
RESEARCH TOOLSreports
Applied Therapeutics (APLT) Stock Price & Analysis
438 Followers
APLT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.18 - $9.39
Previous Close$5.14
Volume26.95K
Average Volume (3M)990.85K
Market Cap
$588.48M
Enterprise Value$441.18M
Total Cash (Recent Filing)$146.50M
Total Debt (Recent Filing)$343.00K
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 08, 2024EPS Estimate
-$0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding114,267,382
10 Day Avg. Volume1,181,087
30 Day Avg. Volume990,850
Standard Deviation0.37
R-Squared0.07
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)7.73
Price to Sales (P/S)52.03
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-924.90
Enterprise Value/Gross Profit44.15
Enterprise Value/Ebitda-2.30
Forecast
1Y Price Target
$12.33Price Target Upside139.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Applied Therapeutics News
PremiumPress Releases
Applied Therapeutics Added to Russell 3000® Index
PremiumCompany Announcements
Applied Therapeutics Welcomes Dale Hooks as New CCO
Bulls Say, Bears Say
Bulls Say
Advisory CommitteeThe newly created Genetic Metabolic Diseases Advisory Committee is expected to include knowledgeable and reasonable members.
Clinical DataAPLT reported promising 12-month clinical outcomes data that demonstrated a correlation between sorbitol level and function as well as significant improvements in a patient reported outcome of disease severity and wellbeing.
Regulatory ProgressThe FDA is not requesting any new clinical data for govorestat, which appears to be a positive indication of the review's progress.
Bears Say
EarningsApplied reported 1Q24 revenue of $0.2M, falling short of the consensus estimate of $3.3M.
Product DevelopmentIt is not surprising that the FDA and EMA have additional questions given govorestat's complicated development history.
RegulatoryThe FDA has extended the review period for the NDA for govorestat in galactosemia by 3 months.
---
Ownership Overview
15.58% Insiders
8.61% Mutual Funds
13.72% Other Institutional Investors
62.09% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APLT FAQ
What was Applied Therapeutics Inc’s price range in the past 12 months?
Applied Therapeutics Inc lowest stock price was $1.18 and its highest was $9.39 in the past 12 months.
What is Applied Therapeutics Inc’s market cap?
Currently, no data Available
When is Applied Therapeutics Inc’s upcoming earnings report date?
Applied Therapeutics Inc’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were Applied Therapeutics Inc’s earnings last quarter?
Applied Therapeutics Inc released its earnings results on May 09, 2024. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of -$0.159 by -$0.511.
Is Applied Therapeutics Inc overvalued?
According to Wall Street analysts Applied Therapeutics Inc’s price is currently Undervalued.
Does Applied Therapeutics Inc pay dividends?
Applied Therapeutics Inc does not currently pay dividends.
What is Applied Therapeutics Inc’s EPS estimate?
Applied Therapeutics Inc’s EPS estimate is -$0.18.
How many shares outstanding does Applied Therapeutics Inc have?
Applied Therapeutics Inc has 114,267,380 shares outstanding.
What happened to Applied Therapeutics Inc’s price movement after its last earnings report?
Applied Therapeutics Inc reported an EPS of -$0.67 in its last earnings report, missing expectations of -$0.159. Following the earnings report the stock price went down -1.911%.
Which hedge fund is a major shareholder of Applied Therapeutics Inc?
Among the largest hedge funds holding Applied Therapeutics Inc’s share is Perceptive Advisors LLC. It holds Applied Therapeutics Inc’s shares valued at 54M.
---
Applied Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (139.42% Upside)
$12.33 (139.42% Upside)
Blogger Sentiment
Bullish
APLT Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
252.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
404.05%
Trailing 12-Months
Company Description
Applied Therapeutics Inc
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
---
APLT Stock 12 Month Forecast
Average Price Target
$12.33
▲(139.42% Upside)
Technical Analysis
Best Analysts Covering APLT
1 Year
1 Year Success Rate
14/28 ratings generated profit
1 Year Average Return
+90.53%
reiterated a buy rating 2 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +90.53% per trade.
---